There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on scPharmaceuticals (SCPH – Research Report), Optinose (OPTN – Research Report) and Biogen (BIIB – Research Report) with bullish sentiments.
scPharmaceuticals (SCPH)
Craig-Hallum analyst Chase Knickerbocker maintained a Buy rating on scPharmaceuticals today. The company’s shares closed last Tuesday at $4.50, close to its 52-week low of $4.25.
According to TipRanks.com, Knickerbocker is a 3-star analyst with an average return of
scPharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $21.25, representing a 384.1% upside. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $18.00 price target.
See the top stocks recommended by analysts >>
Optinose (OPTN)
Lake Street analyst Thomas Flaten maintained a Buy rating on Optinose today. The company’s shares closed last Tuesday at $1.13.
According to TipRanks.com, Flaten is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Optinose with a $4.00 average price target, which is a 244.8% upside from current levels. In a report released today, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.
Biogen (BIIB)
Jefferies analyst Michael Yee assigned a Buy rating to Biogen on May 10 and set a price target of $285.00. The company’s shares closed last Tuesday at $226.88.
According to TipRanks.com, Yee is a 2-star analyst with an average return of
Biogen has an analyst consensus of Strong Buy, with a price target consensus of $289.57, implying a 28.1% upside from current levels. In a report issued on April 25, Truist Financial also maintained a Buy rating on the stock with a $340.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SCPH:
- scPharmaceuticals Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- scPharmaceuticals to Present at the H.C. Wainwright 2nd Annual BioConnect Investor Conference
- scPharmaceuticals management to meet with Craig-Hallum
- SCPH Earnings this Week: How Will it Perform?
- scPharmaceuticals to Announce First Quarter 2024 Financial Results on Tuesday, May 14, 2024
